Table 2.
Univariate and multivariate p values of tumor and nontumor related risk factors for HCC recurrence after LT. The nontumor related risk factors were analyzed stratified for the most dominant tumor related risk factor (microvascular invasion).
| Univariate | Multivariate | |
|---|---|---|
| Tumor factors: | ||
| Microvascular invasion | <0.001 | <0.001 |
| Number of tumor nodules (≤3 versus >3) | <0.001 | 0.138 |
| Maximum diameter (≤5 versus >5 cm) | 0.001 | 0.934 |
| AFP level | 0.006 | 0.495 |
| HCC incidentally detected after LT | 0.108 | |
|
| ||
| Nontumor factors: | ||
| Tumor biopsy | 0.015 | 0.884 |
| Blood transfusions | 0.023 | 0.033 |
| Age (≤60 versus >60 years) | 0.045 | 0.118 |
| Waiting time | 0.091 | |
| Child Pugh status | 0.175 | |
| Sirolimus after LT | 0.183 | |
| Underlying liver disease | 0.208 | |
| Cyclosporine (versus tacrolimus) | 0.280 | |
| Haemodialysis | 0.343 | |
| Immunosupp. (dual versus triple versus quadruple) | 0.362 | |
| ATG induction therapy | 0.398 | |
| Pervious liver resection for HCC | 0.481 | |
| Gender | 0.496 | |
| OKT 3 therapy | 0.524 | |
| Piggy back | 0.567 | |
| Azathioprine | 0.571 | |
| IL-2 induction therapy | 0.614 | |
| Antirejection therapy (antibodies, steroids) | 0.646 | |
| Mycophenolate | 0.674 | |
| Duration of ICU treatment | 0.746 | |
| Period of LT | 0.859 | |
| Blood group | 0.891 | |
| TACE before LT | 0.960 | |